Urine CrossLaps? (CTX-I) EIA 品牌Immunoassay Systems | IDS

點(diǎn)擊看大圖

如果您對(duì)該產(chǎn)品感興趣的話,可以

產(chǎn)品名稱(chēng): Urine CrossLaps? (CTX-I) EIA 品牌Immunoassay Systems | IDS

產(chǎn)品型號(hào): AC-03F1

產(chǎn)品展商: 其他品牌

產(chǎn)品文檔: 無(wú)相關(guān)文檔

簡(jiǎn)單介紹

品名：Urine CrossLaps? (CTX-I) EIA 貨號(hào)：AC-03F1

Urine CrossLaps? (CTX-I) EIA 品牌Immunoassay Systems | IDS 的詳細(xì)介紹

Code:	AC-03F1
Certification:	CE Marked
Clinical Area:	Bone Metabolism
Type:	Manual
Format:	EIA
RUO/IVD:	IVD
Number of Tests:	96 (40 samples in duplicate)
Sample Type:	Urine
Sample Volume:	15 μL
Assay Range:	0-6750 ng/mL

Unique Features

Management of Postmenopausal Osteoporosis
Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
Increase patient motivation and compliance
Assessment of Bone Resorption in patients
With metabolic bone disease, e.g. hyperparathyroidism, Paget′s disease, osteodystrophy
Receiving prolonged glucocorticoid therapy
A complete clinical assay panel supporting bone disease management

Product Description

The Urine CrossLaps® (CTX-I) EIA is an enzyme immunosorbent assay for quantitative determination of degradation products of C-terminal telopeptides of Type-I collagen in human urine.

The Urine CrossLaps® (CTX-I) EIA assay is intended for in vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:
Monitoring bone resorption changes of:

Anti-resorptive therapies in postmenopausal women:

Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate therapies

Anti-resorptive therapies in individuals diagnosed with osteopenia:

Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate therapies.

Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies:

Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate

Scientific Description

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone.

During renewal of the skeleton, Type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can be measured by Urine CrossLaps® (CTX-I) EIA as has been reported as useful for follow up of anti-resorptive treatment of patients with metabolic bone diseases 1, 2, 3.

Publications

Buclin T et al., Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002 Aug;17(8):1478-85.

Garnero P. et al., Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int (1998); 8: 563-569.

Nagase S et al., Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women. J Bone Miner Metab. 2014 Jan 24.